Inmune Bio (INMB) Operating Leases (2019 - 2026)
Inmune Bio (INMB) posted Operating Leases of $1.5 million for Q1 2026, up 267.4% sequentially from $411000.0 in Q4 2025, and up 651.24% YoY from $201000.0 in Q1 2025.
Inmune Bio (INMB) Operating Leases (2019 - 2026) Analysis & Trends
Inmune Bio has reported Operating Leases for 8 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Operating Leases rose 651.24% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 651.24% YoY) and the FY2025 annual result came in at $411000.0, up 68.44% from the prior year.
- Operating Leases improved to $1.5 million in Q1 2026 per INMB's latest filing, from $411000.0 in the prior quarter.
- Over five years, Operating Leases peaked at $1.5 million in Q1 2026 and troughed at $201000.0 in Q1 2025.
- A 5-year average of $518764.7 and a median of $430000.0 in 2023 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2025 and 2026: Operating Leases tumbled 44.17% in 2025, then soared 651.24% in 2026.
- Over 5 years, Operating Leases stood at $613000.0 in 2022, then tumbled by 35.24% to $397000.0 in 2023, then slumped by 38.54% to $244000.0 in 2024, then surged by 68.44% to $411000.0 in 2025, then surged by 267.4% to $1.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $1.5 million, $411000.0, and $623000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Inmune Bio | 62.12 Mn | 43.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 411,000.00 |
| Sep 30, 2025 | 623,000.00 |
| Jun 30, 2025 | 231,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 244,000.00 |
| Sep 30, 2024 | 284,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 397,000.00 |
| Sep 30, 2023 | 430,000.00 |
| Jun 30, 2023 | 564,000.00 |
| Mar 31, 2023 | 498,000.00 |
| Dec 31, 2022 | 613,000.00 |
| Sep 30, 2022 | 607,000.00 |
| Jun 30, 2022 | 758,000.00 |
| Mar 31, 2022 | 766,000.00 |
| Dec 31, 2021 | 284,000.00 |
| Sep 30, 2021 | 95,000.00 |